For example, Sorafenib, a VEGFR, PDGFR, KIT, FLT3, and RAF inhibitor, was recently evaluated in clinical trials for its effectiveness against gastrointestinal stromal tumors [65]. This evidence concerns the gene PDGFRB and gastrointestinal stromal tumor.